Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans

As the demand for rabies post-exposure prophylaxis (PEP) treatments has increased exponentially in recent years, the limited supply of human and equine rabies immunoglobulin (HRIG and ERIG) has failed to provide the required passive immune component in PEP in countries where canine rabies is endemic. Replacement of HRIG and ERIG with a potentially cheaper and efficacious alternative biological for treatment of rabies in humans, therefore, remains a high priority. In this study, we set out to assess a mouse monoclonal antibody (MoMAb) cocktail with the ultimate goal to develop a product at the lowest possible cost that can be used in developing countries as a replacement for RIG in PEP. Five MoMAbs, E559.9.14, 1112-1, 62-71-3, M727-5-1, and M777-16-3, were selected from available panels based on stringent criteria, such as biological activity, neutralizing potency, binding specificity, spectrum of neutralization of lyssaviruses, and history of each hybridoma. Four of these MoMAbs recognize epitopes in antigenic site II and one recognizes an epitope in antigenic site III on the rabies virus (RABV) glycoprotein, as determined by nucleotide sequence analysis of the glycoprotein gene of unique MoMAb neutralization-escape mutants. The MoMAbs were produced under Good Laboratory Practice (GLP) conditions. Unique combinations (cocktails) were prepared, using different concentrations of the MoMAbs that were capable of targeting non-overlapping epitopes of antigenic sites II and III. Blind in vitro efficacy studies showed the MoMab cocktails neutralized a broad spectrum of lyssaviruses except for lyssaviruses belonging to phylogroups II and III. In vivo, MoMAb cocktails resulted in protection as a component of PEP that was comparable to HRIG. In conclusion, all three novel combinations of MoMAbs were shown to have equal efficacy to HRIG and therefore could be considered a potentially less expensive alternative biological agent for use in PEP and prevention of rabies in humans.

[1]  E. Ooi,et al.  The use of antibodies in the treatment of infectious diseases. , 2009, Singapore medical journal.

[2]  S. Kostense,et al.  First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. , 2008, Vaccine.

[3]  N. Tordo,et al.  Complete genomes of Aravan, Khujand, Irkut and West Caucasian bat viruses, with special attention to the polymerase gene and non-coding regions. , 2008, Virus research.

[4]  F. Conraths,et al.  Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife. , 2008, Vaccine.

[5]  J. C. Almagro,et al.  Humanization of antibodies. , 2008, Frontiers in bioscience : a journal and virtual library.

[6]  V. Ravi,et al.  Use of Neutralizing Murine Monoclonal Antibodies to Rabies Glycoprotein in Passive Immunotherapy Against Rabies , 2007, Human vaccines.

[7]  J. Blanton,et al.  Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. , 2007, Vaccine.

[8]  C. Rupprecht,et al.  A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. , 2007, Annual review of medicine.

[9]  M. Molyneux,et al.  Rabies Encephalitis in Malaria-Endemic Area, Malawi, Africa , 2007, Emerging infectious diseases.

[10]  C. Hanlon,et al.  Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. , 2006, The Journal of infectious diseases.

[11]  C. Jallet,et al.  A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[12]  T. Lembo.  WHO Expert Consultation on rabies. , 2010, World Health Organization technical report series.

[13]  A. Fooks,et al.  Pivotal Role of Dogs in Rabies Transmission, China , 2005, Emerging infectious diseases.

[14]  A. Fooks.  Rabies remains a 'neglected disease'. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  N. Johnson,et al.  Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. , 2005, Vaccine.

[16]  C. Rupprecht,et al.  Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. , 2005, Virus research.

[17]  J. Blanton,et al.  Efficacy of rabies biologics against new lyssaviruses from Eurasia. , 2005, Virus research.

[18]  Jaap Goudsmit,et al.  Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants , 2005, Journal of Virology.

[19]  M. Meltzer,et al.  Re-evaluating the burden of rabies in Africa and Asia. , 2005, Bulletin of the World Health Organization.

[20]  Who Expert Consultation on Rabies.  WHO Expert Consultation on Rabies : first report , 2005 .

[21]  J. Teillaud,et al.  Future Prospects in Antibody Engineering and Therapy , 2004 .

[22]  C. Hanlon,et al.  Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. , 2003, The Journal of infectious diseases.

[23]  P. Perrin,et al.  Differential stability and fusion activity of Lyssavirus glycoprotein trimers. , 2003, Virus research.

[24]  C. Hanlon,et al.  Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. , 2001, Vaccine.

[25]  M. Schnell,et al.  High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. , 2001, Journal of immunological methods.

[26]  N. Tordo,et al.  Evidence of Two Lyssavirus Phylogroups with Distinct Pathogenicity and Immunogenicity , 2001, Journal of Virology.

[27]  C. Rupprecht,et al.  The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. , 2000, Journal of immunological methods.

[28]  C. Jallet,et al.  Chimeric Lyssavirus Glycoproteins with Increased Immunological Potential , 1999, Journal of Virology.

[29]  M. Aubert,et al.  Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. , 1998, Journal of immunological methods.

[30]  Notkins Al,et al.  Production of human monoclonal antibodies against rabies virus. , 1994 .

[31]  W. Kajiyama,et al.  Development of human monoclonal antibodies to rabies. , 1994, Hybridoma.

[32]  A. Notkins,et al.  Production of human monoclonal antibodies against rabies virus. , 1994, Current topics in microbiology and immunology.

[33]  C. Rupprecht,et al.  Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Bouvet,et al.  Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. , 1990, The Journal of general virology.

[35]  P. Casali,et al.  Biological characterization of human monoclonal antibodies to rabies virus , 1990, Journal of virology.

[36]  C. Rupprecht,et al.  Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. , 1989, The Journal of clinical investigation.

[37]  S. Chutivongse,et al.  Adverse effects of equine rabies immune gobulin. , 1989, Vaccine.

[38]  S. Chutivongse,et al.  Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. , 1989, Bulletin of the World Health Organization.

[39]  C. Rupprecht,et al.  Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies. , 1988, Reviews of infectious diseases.

[40]  H. Koprowski,et al.  Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. , 1987, Virology.

[41]  H. Koprowski,et al.  Rabies in the Tropics , 1985, Springer Berlin Heidelberg.

[42]  B. Barnard,et al.  Application of Monoclonal Antibodies for Epidemiological Investigations and Oral Vaccination Studies , 1985 .

[43]  H. Koprowski,et al.  Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. , 1984, Developments in biological standardization.

[44]  T. Wiktor,et al.  Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. , 1983, The Journal of general virology.

[45]  B. Dietzschold,et al.  Chemical and immunological analysis of the rabies soluble glycoprotein. , 1983, Virology.

[46]  C. Macek.  Monoclonal antibodies: key to a revolution in clinical medicine. , 1982, JAMA.

[47]  H. Kaplan,et al.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[48]  L. Schneider,et al.  Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine , 1976, Journal of clinical microbiology.

[49]  P. Yager,et al.  A rapid reproducible test for determining rabies neutralizing antibody. , 1973, Bulletin of the World Health Organization.